Abstract:Objectives (1) To assess if co-administration of four-component meningococcal serogroup B vaccine (4CMenB) and other routine vaccines caused an interaction increasing the risk and/or severity of adverse events following immunisation (AEFI) compared with administration at separate visits and (2) to estimate the risk of AEFI recurrence. Design Risk-interval design Setting Three randomised controlled trials conducted in Europe. Participants A total of 5026 healthy 2-month-old to 15-month-old infants. Interventions 4CMenB and routine vaccines (hexavalent combined diphtheria-tetanus-acellular pertussis-inactivated polio-Haemophilus influenzae type b-hepatitis B vaccine+seven-valent pneumococcal conjugate vaccine or measles-mumps-rubella-varicella vaccine) administered concomitantly or separately 1 month apart, in regular (2, 4, 6 and 12 months), accelerated (2, 3, 4 and 12 months) or delayed (two doses of 4CMenB at ≥12 months of age) schedules. Outcome measures Primary: Fever (≥38°C) during the first 48 hours post immunisation. Secondary: crying, change in eating habits, diarrhoea, irritability and tenderness at the 4CMenB injection site. Results Compared with separate administration, concomitant administration decreased the overall incidence of fever (≥38°C), 86% versus 75%, and other systemic AEFIs but increased the incidence of 4CMenB injection site tenderness, 55% versus 66%, moderate/severe fevers (≥39°C), 13% versus 18%, and long-lasting (>1 day) fevers, 23% versus 33%. Co-administration reduced AEFI risk by 4%–49% with the greatest impact among infants with prior AEFI(s). Fever recurrence risk was proportional to the number of prior fever events: 79% at dose 2 with one prior episode; 44% and 74% at dose 3 with one and two prior episodes, respectively; and 29%, 45% and 60% at dose 4 with one, two and three prior episodes, respectively. Severity was not increased at recurrence and a similar pattern of recurrence risk proportional to the number of prior events was observed for other AEFIs. Conclusions The cumulative risk of AEFI is reduced with concomitant versus separate administration of 4CMenB and routine infant vaccines. Infants with a prior AEFI are at higher risk of the same AEFI at subsequent immunisations, but severity with recurrence is usually not increased. Trials registration number NCT00657709 , NCT00847145 , NCT00721396 and NCT02712177 ; Pre-results.

Adverse events following immunisation: Prospective cohort study evaluating Australian children presenting to specialist immunisation clinics

Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study

What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety

Factors associated with intention for revaccination among patients with adverse events following immunization

Occurrence of adverse events following vaccination in patients with allergies: a prospective study

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials

Incomplete Vaccination among Children with Special Health Care Needs in Zhejiang, China: Analysis of Retrospective Data

Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: A population-based retrospective cohort study.

Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data

Vaccination Experiences of Premature Children in a Retrospective Hospital-Based Cohort in a Chinese Metropolitan Area.

Adverse Events Following Immunization- The Known Unknowns and Black Box

Consumer reporting of adverse events following immunization

Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study

Factors influencing adverse events following COVID-19 vaccination

Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination

Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center

Genetic Predisposition to Adverse Events in Chinese Children Aged 3-24 Months after Diphtheria, Tetanus, Acellular Pertussis and Haemophilus Influenzae Type B Combined Vaccination

An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Subcutaneous nodules: an important adverse event following immunization

Investigating the Potential Short-term Adverse Effects of the Quadrivalent Human Papillomavirus Vaccine: A Novel Regression Discontinuity Analysis